🚀 Kicking off Nucleate Germany’s Activator 2025!
🛡️⚖️ This week, we gathered at Vossius & Partner in Munich for an inspiring start teams met, collaborated, and dove into their first workshop on IP strategy.
More updates & the Activator 2025 teams announcement coming soon! 👥
What if machine learning could revolutionize gene therapy? That’s exactly what Eric Kelsic, CEO of Dyno Therapeutics, is doing!
Listen to the full episode here: https://t.co/lpVxMpXV1A
#GeneTherapy#AI#Biotech#Innovation#MachineLearning#AAV
🚀 Kicking off 2025 with an incredible Nucleate Germany event in Munich!
A huge thank you to the scientists, entrepreneurs & innovators who joined.
🗓️ Stay tuned for more events - let’s shape the future, together!
@NucleateHQ
👥 Founder Focus: Building a Biotech Ecosystem with Nucleate Germany
We’re hosting a workshop at SynBioReactor, organized by @gasb_synbio, to explore biotech entrepreneurship & the Nucleate Activator Program!
🚀 Join us & share your insights - let’s build together!
@NucleateHQ
Check out the latest episode of the Nucleate Podcast featuring Jake Becraft, co-founder and CEO of Strand Therapeutics, who shares his journey from MIT to building a clinical-stage biotech company revolutionizing mRNA therapeutics. https://t.co/p5qQIP0tdu
personalized medicine, sustainability, and more.
It was an inspiring conversation, and we look forward to seeing the impact that Nucleate, TUM, and the broader biotech and sustainability community will make in the years to come.
Thank you, Prof. Dr. Hofmann and the team!
This week, our team had the pleasure of meeting Prof. Dr. Thomas F. Hofmann, the President of @TU_Muenchen (TUM), as well as Dr. Olga Malets and Julia Hinderink from TUM ForTe.
We discussed...
ways to foster entrepreneurship in biotech and sustainability at TUM and in Germany as a whole.
We touched upon the need for interdisciplinary collaboration, the importance of fostering a strong startup culture, and the potential for innovation in areas such as...
👉 Links
- Full announcement: https://t.co/XLgQooxbAv
- List of the 143 ventures: https://t.co/m9P55ztmNp
- Information for potential mentors: https://t.co/ZVPev5ULKt
Meet the 143 biotech venture teams who participate in Nucleate's 2023 Activator, the first international cycle of the program.
The teams are addressing crucial global challenges - such as human disease, the climate crisis, and food scarcity - with their scientific breakthroughs.
We invite experienced bio founders, executives, investors, and scientists to join us in mentoring this year's teams, as we work to foster technology translation and create a strong community of biotech innovators.
@NucleateGermany is partnering with hei_INNOVATION, the tech transfer office of @UniHeidelberg , to drive growth and development through cutting-edge biotech innovations. Our partnership is a step towards making Germany a leading biotech hub.
"If we unlock the potential of European life sciences founders, we can address this century's greatest challenges," says BlueYard co-founder @jason_whitmire
👉 If you are curious about joining Nucleate or working with us, please reach out! We are more than happy to talk.
👉 A link to the full announcement: https://t.co/JvZWezxIQW
Unified with all Nucleate chapters worldwide, we are building the world’s largest educational organization for the next generation of bioentrepreneurs, biotech leaders, and venture capitalists.